
Globus Medical (GMED) Stock Forecast & Price Target
Globus Medical (GMED) Analyst Ratings
Bulls say
Globus Medical is viewed favorably because its core spine franchise, strengthened by the 2023 NuVasive merger, remains supported by premium gross margin of 69.5%, adjusted EBITDA margin of 34.3%, and reiterated FY26 EPS of $4.95-5.05 despite a temporary revenue shortfall. The 2025 Nevro acquisition and rapid Enabling Technologies growth, up 24% with units deployed up 73%, add diversification and create upside as delayed launches and rep productivity issues are described as transient rather than demand-driven. With management targeting MSD-HSD growth in 2027 and expecting margin expansion toward the mid-30% range, the company still appears positioned for double-digit EPS power and further free cash flow growth.
Bears say
Globus Medical is facing a negative fundamental setup because its growth thesis depends on successful integration of the NuVasive and Nevro mergers, yet those deals also create meaningful disruption risk and potential revenue dis-synergies. The bear case points to revenue growth slowing to the low-single digits with flat margins, while downside drivers include weaker spine market growth, reimbursement and pricing headwinds, and operating margin compression versus expectations. Additional pressure comes from lower-than-expected Enabling Technologies sales, slower robotic purchasing, and product launches or expansion into trauma, hips, and knees that may take longer to gain traction.
This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.
Globus Medical (GMED) Analyst Forecast & Price Prediction
Start investing in Globus Medical (GMED)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Globus Medical (GMED) Forecast
Globus Medical (GMED) Analyst Forecast & Price Prediction
Start investing in Globus Medical (GMED)
Order type
Buy in
Order amount
Est. shares
0 shares